What Is Elecoglipron?

1. How Does Elecoglipron Work?

Elecoglipron is a small molecule that activates the GLP-1 receptor. Early research in human beta-cell lines and monkeys showed it enhanced glucose-stimulated insulin secretion, and the first human study supported once-daily oral dosing (first-in-human study). Earlier publications use the codes ECC5004 and AZD5004 for the same molecule.

The Lancet paper describes it as taken once daily without food or fluid restriction (VISTA publication). That is a practical difference from oral semaglutide, a peptide that must be swallowed on an empty stomach. Elecoglipron is a different molecule from both semaglutide and orforglipron, even though all three act on the same receptor.

2. Where Did Elecoglipron Come From?

Elecoglipron was not an AstraZeneca discovery. It was developed by Eccogene as ECC5004, and AstraZeneca licensed it in November 2023 for $185 million upfront and up to $1.825 billion in later milestones, with the two companies co-developing it in China (license announcement).

That history explains the two codes. ECC5004 appears in the first-in-human paper and in early registry entries; AZD5004 appears from the Phase 2 program onward. AstraZeneca now uses the generic name elecoglipron in its own materials (Phase 3 announcement).

3. What Did VISTA Show for Weight Loss?

VISTA randomized 310 adults without diabetes who had obesity, or overweight with a weight-related condition, across seven countries. Participants were typical of obesity trials: 73% were women, average weight was 107 kg, and average BMI was 38. The trial ran 36 weeks, with the main weight endpoints assessed at week 26, and is registered as NCT06579092 (VISTA publication).

The chart shows the best-performing of five dosing arms. Two arms used fixed low doses, 5 mg and 15 mg, with no escalation. Three climbed to a higher target: 50 mg in steps every four weeks, 75 mg in steps every two weeks, and 75 mg in weekly steps. At week 26 mean weight change ran from −2.6% at 5 mg to −10.5% on the weekly-step 75 mg arm, against −0.6% on placebo; the second 75 mg arm, stepped up every two weeks, reached −10.0%. The share of participants losing at least 5% of body weight ran from 40% at the lowest dose to 89% at the highest, against 16% on placebo (VISTA publication). The 5 mg tablet added only about 2 percentage points over placebo; the headline numbers depend on reaching a high dose.

These efficacy-estimand results estimate effects assuming treatment is followed as intended. Adherence was imperfect: 93% of participants finished the study, but only 75% finished the treatment they were assigned (VISTA publication). Results counting everyone regardless of adherence would likely be smaller.

4. What Did SOLSTICE Show for Type 2 Diabetes?

SOLSTICE randomized 406 adults, of whom 404 received treatment. Participants had type 2 diabetes with HbA1c between 7.0% and 10.5%, managed with lifestyle measures alone, metformin, or an SGLT2 inhibitor. Average baseline HbA1c was 7.9%. The study compared eight groups: elecoglipron at 5, 15, or 25 mg without escalation, 50 mg reached in steps every two weeks, 75 mg reached in steps every two or four weeks, matched placebo, and open-label oral semaglutide titrated to 14 mg (SOLSTICE publication).

The primary result was HbA1c change at 26 weeks. It fell by 0.91 percentage points at 5 mg and by 1.88 points with the 75 mg regimen escalated every two weeks, versus 0.15 points with placebo. On that top regimen, 90% of participants reached an HbA1c below 7% and 85% reached 6.5% or lower, the targets most guidelines use (ADA summary).

Weight loss in this diabetes population was smaller than in VISTA: 7.7% on the top regimen versus 1.7% with placebo. That gap between diabetes and non-diabetes trials is normal for the GLP-1 class, and it is why the two Phase 2 results should not be averaged together.

The oral semaglutide arm was open-label and included only for exploratory comparison. AstraZeneca reported HbA1c down 1.3 points and weight down 5.1% on semaglutide 14 mg, against 1.9 points and 7.7% on the top elecoglipron regimen, but this was not a powered comparison (AstraZeneca results release). The formal head-to-head test is ELUMINATE-2, described below.

5. What Side Effects Were Reported, and Does Escalation Speed Matter?

Digestive symptoms were prominent. AstraZeneca reported the following rates for VISTA’s highlighted 75 mg group (June 2026 safety report):

In SOLSTICE, the 75 mg rates were lower: nausea 37% versus 3% on placebo, constipation 29% versus 4%, diarrhea 21% versus 15% and vomiting 18% versus 1%. AstraZeneca said discontinuations for adverse events were infrequent and that the Phase 2 tolerability data informed the escalation schedule chosen for Phase 3 (AstraZeneca results release).

Two details from the Lancet papers add context. First, any adverse event was reported by 84% to 98% of participants across VISTA’s elecoglipron arms against 84% on placebo, and by 63% to 87% across SOLSTICE’s against 63% on placebo, so the lowest-dose arms matched placebo. Second, the two 75 mg schedules in VISTA ended close together, 10.5% with weekly steps and 10.0% with steps every two weeks at week 26, so faster escalation added little extra weight loss (VISTA, SOLSTICE, AstraZeneca results release).

The company reported no liver safety signal in these trials. Longer-term and uncommon risks remain under study.

6. How Does It Compare With Orforglipron and Oral Semaglutide?

Four oral GLP-1 medicines now sit in the same conversation:

Wegovy pill status and dosing rules: Novo Nordisk approval announcement and Wegovy label.

Elecoglipron’s practical pitch is the same as orforglipron’s: a tablet without the fasting routine that oral semaglutide requires. Its strategic pitch, according to AstraZeneca, is use both alone and in combinations, starting with dapagliflozin in the ELUMINATE diabetes trials, plus cardiovascular and kidney outcome trials (Phase 3 announcement).

Whether it works better than any of these rivals is unknown. VISTA and SOLSTICE compared it with placebo, and cross-trial comparisons of weight-loss percentages are unreliable because populations, durations and analysis methods differ. Two other oral small molecules, aleniglipron and HRS-7535, are also in late-stage development, on different timelines.

7. What Are EMBOLD and ELUMINATE Testing?

EMBOLD contains two independent pivotal studies: one without type 2 diabetes and one with it. The registered master protocol plans approximately 4,500 participants and compares elecoglipron with placebo alongside diet and exercise. Its primary weight endpoint is at 72 weeks, twice the length of VISTA, which will show whether weight loss keeps going or levels off (EMBOLD registry).

ELUMINATE-2 is a direct comparison with oral semaglutide in approximately 1,200 adults with type 2 diabetes at increased cardiovascular risk. It is randomized and open-label, meaning treatment assignment is known (ELUMINATE-2 registry).

ELUMINATE-4 examines elecoglipron versus placebo in adults with type 2 diabetes and impaired kidney function receiving background dapagliflozin (Japanese trial registration).

Other ELUMINATE trials test elecoglipron alone or with dapagliflozin versus placebo in about 800 adults (ELUMINATE-1), versus placebo on background insulin in about 600 (ELUMINATE-3), and the elecoglipron-dapagliflozin combination against each drug alone in about 2,000 (ELUMINATE-5). Each measures HbA1c change at 40 weeks (ELUMINATE-1, ELUMINATE-3, ELUMINATE-5).

Outcome Trials

Two large event-driven outcome trials began in August 2026, both versus placebo on top of background dapagliflozin. ELEVATE-HF plans about 6,950 adults with heart failure with preserved or mildly reduced ejection fraction, with or without diabetes, and measures cardiovascular death or heart-failure events (ELEVATE-HF registry). ELEVATE-CKD plans about 7,000 adults with chronic kidney disease, with or without diabetes, and measures sustained kidney-function decline, kidney failure or death (ELEVATE-CKD registry). These trials test organ protection, not weight loss, and read out after the EMBOLD weight results.

Phase 3 Timeline

There is no confirmed approval date. These are the currently listed study milestones:

Sources: Phase 3 announcement, EMBOLD, ELUMINATE-2, ELEVATE-HF, and ELEVATE-CKD.

Primary completion marks collection of primary-endpoint data; regulatory review and launch would follow separately.

8. Elecoglipron FAQ

• Is elecoglipron the same as AZD5004 or ECC5004?

  Yes. Elecoglipron is the drug name; AZD5004 and ECC5004 are development codes for the same investigational molecule. ECC comes from Eccogene, which discovered it, and AZD from AstraZeneca, which licensed it.

• How is elecoglipron taken?

  In its trials it was a once-daily tablet with no food or fluid restriction. That differs from Rybelsus, whose label requires an empty stomach and a 30-minute wait before eating. Higher target doses were reached by stepping up over several weeks.

• Is elecoglipron approved or available to buy?

  It remains investigational as of October 15, 2026, with no confirmed launch date or retail price. The 2028 Phase 3 completion estimates are study milestones, not release dates.

• When could elecoglipron be approved?

  No date exists. EMBOLD's primary weight endpoint is due in mid-2028, and a filing can only follow that readout, so an approval before 2029 would be unusual. Orforglipron, a rival oral small molecule, was approved as Foundayo in April 2026, so elecoglipron will not be the first of its kind.

• Is elecoglipron oral semaglutide?

  No. It is a separate small molecule. SOLSTICE ran an open-label oral semaglutide 14 mg arm alongside it, and ELUMINATE-2 is now comparing the two directly in adults with type 2 diabetes.

9. Sources